New hope for Hard-to-Treat lymphoma? early trial of ABBV-291 begins

NCT ID NCT06667687

Ongoing Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or stopped responding to treatment. The study will first find the safest dose, then check if the drug can shrink tumors. About 165 participants will take part worldwide.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABBV-291 (given as an intravenous infusion)
What this could lead to: If it works, this could point toward a new treatment option for people with Non-Hodgkin's lymphoma that has not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial, so the drug may not work or could have serious side effects. It is also a small study, so results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma Lymphoma, B-Cell, Marginal Zone mantle cell lymphoma marginal zone lymphoma neoplasm non-Hodgkin lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN'S LYMPHOMA

Contacts and locations

Locations

Aichi Cancer Center /ID# 267471

Nagoya, Aichi-ken, 464-8681, Japan
Carolina BioOncology Institute /ID# 265259

Huntersville, North Carolina, 28078, United States
Hadassah Medical Center-Hebrew University /ID# 261658

Jerusalem, Jerusalem, 91120, Israel
National Cancer Center Hospital East /ID# 261775

Kashiwa-shi, Chiba, 277-8577, Japan
START Mountain Region /ID# 267592

West Valley City, Utah, 84119-3602, United States
Sir Charles Gairdner Hospital /ID# 268579

Nedlands, Western Australia, 6009, Australia
St Vincent's Hospital Melbourne /ID# 261664

Fitzroy Melbourne, Victoria, 3065, Australia
Tel Aviv Sourasky Medical Center /ID# 261659

Tel Aviv, Tel Aviv, 6423906, Israel
Texas Oncology - Central/South Texas /ID# 270946

Austin, Texas, 78705, United States
The Cancer Institute Hospital Of JFCR /ID# 267470

Koto-ku, Tokyo, 135-8550, Japan
The Christie /ID# 267177

Manchester, M20 4BX, United Kingdom
University Hospitals Plymouth NHS Trust /ID# 267174

Plymouth, PL6 5FP, United Kingdom
Virginia Cancer Specialists - Fairfax /ID# 265082

Fairfax, Virginia, 22031, United States
Willamette Valley Cancer Institute and Research Center /ID# 270945

Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.